Pierianbio.com Website Review

pierian biosciences is focused on the development and delivery of innovative as*ays and an*lytical approaches in the rapidly changing. the advanced cytometric as*ay capabilities developed by pierian biosciences provide valuable information to aid pharmaceutical companies from early-stage drug development through clinical validation of new thera*eutics.  the aspiration is to improve patient outcomes and lower health care costs through the application of the immunointel and chemointel platforms. a comprehensive functional immuno-as*ay focused on intra-tumoral and peripheral “markers” of immune system activation and competence to a functional multi-parametric chemosensitivity as*ay providing actionable information guiding the selection of the most effective. pierian biosciences to present immunointel platform at annual sitc conference. pierian biosciences will present a poster with new data on immunointel, at the 33rd annual meeting of the society for immunotherapy of cancer, to be held november 7-11, 2018 at the walter e. washington convention center in washington, d.c. the poster, “immunointel, a flow cytometry based platform that identifies and quantifies the most critical cell subsets and related functional recent published results (aacr 2018 and nejm) from the merck keynote-189 trial in non-squamous non-small cell lung cancer (nsclc) proved to be very exciting in the world of oncology. the study showed that patients treated with pembrolizumab (keytruda™) plus chemotherapy had significantly longer overall survival (os) and progression-free survival (pfs) compared with those who received chemotherapy alone, meeting both its primary endpoints. read more we use cookies to an*lyze our traffic and we share information about your use of our site with our an*lytics partners. our partners may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. continuing to use this website, you acknowledge that you have read and agree to the terms of the updated privacy policy